Posts by: Jose Marques Lopes, PhD

News

Idiopathic pulmonary fibrosis (IPF) oral treatment candidate PLN-74809 can prevent the activation of the pro-fibrotic protein TGF-beta by up to 70% in healthy volunteers, according to final results of ... Read more

May 28, 2019June 18, 2019

Potential IPF Therapy Remlarsen Mimicking RNA Molecule Effective in Mouse Model

News

An idiopathic pulmonary fibrosis (IPF) treatment candidate that mimics a tiny RNA molecule lowered the production of key profibrotic proteins and blocked fibrosis development in a mouse model of the ... Read more

March 11, 2019March 12, 2019

Stem Cell Therapies Should Not Be Received Outside Clinical Trials, PF Foundation Says

News

The medical advisory board of the Pulmonary Fibrosis Foundation (PFF) strongly cautions patients with pulmonary fibrosis (PF) not to receive stem cell or cell-based treatments outside an approved clinical ... Read more

March 4, 2019March 4, 2019

Novel NOX4 Blockers Could Treat Fibrosis at the Source, Scientists Say

News

Novel selective blockers of the NOX4 enzyme could ease oxidative stress and the subsequent development of fibrosis in lungs and other organs, according to scientists at the University of Arizona. ... Read more

February 13, 2019February 14, 2019

Vitamin D Deficiency Linked to Disease Severity, Mortality Risk in IPF Patients, Study Shows

News

Vitamin D deficiency in patients with idiopathic pulmonary fibrosis (IPF) is associated with functional and clinical predictors of disease severity and a higher risk of mortality, according to a ... Read more

February 12, 2019February 12, 2019

PU.1 Inhibition May Help Treat PF, Other Fibrotic Disorders

News

A protein called PU.1 plays a central role in the deposition of connective tissue during fibrosis, according to new research. The findings also suggested that blocking PU.1 may be ... Read more

January 30, 2019February 5, 2019

Esbriet Extends Long-term Survival, Slows IPF Progression, Real-life Study Reveals

Esbriet, News

Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline in lung function at two years, according to a real-life study ... Read more

January 15, 2019January 15, 2019

Size of Healthy Lung Area Can Help Predict Survival in CPFE Patients with Lung Cancer, Study Says

News

Evaluating the lung area that is normal, or healthy, can help predict the survival of patients with combined pulmonary fibrosis and emphysema (CPFE) at the time of lung cancer ... Read more

January 9, 2019January 16, 2019

Phase 1 Study of Potential IPF Therapy, PLN-74809, Doses 1st Group, Pliant Says

News

A Phase 1 trial of an investigational treatment for idiopathic pulmonary fibrosis (IPF), PLN-74809, has dosed a first group of healthy participants, Pliant Therapeutics announced. PLN-74809, the company’s lead candidate, is a ... Read more

January 2, 2019January 3, 2019

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

IPF Therapy PLN-74809 Well-tolerated, Suppresses Pro-fibrotic Signals, Phase 1b Trial Shows

Potential IPF Therapy Remlarsen Mimicking RNA Molecule Effective in Mouse Model

Stem Cell Therapies Should Not Be Received Outside Clinical Trials, PF Foundation Says

Novel NOX4 Blockers Could Treat Fibrosis at the Source, Scientists Say

Vitamin D Deficiency Linked to Disease Severity, Mortality Risk in IPF Patients, Study Shows

PU.1 Inhibition May Help Treat PF, Other Fibrotic Disorders

Esbriet Extends Long-term Survival, Slows IPF Progression, Real-life Study Reveals

Size of Healthy Lung Area Can Help Predict Survival in CPFE Patients with Lung Cancer, Study Says

Phase 1 Study of Potential IPF Therapy, PLN-74809, Doses 1st Group, Pliant Says

Top 10 Pulmonary Fibrosis Stories of 2018

Pin It on Pinterest